home / stock / cybn:cc / cybn:cc news

CYBN:CC News and Press, CYBIN INC. From 08/04/23

Stock Information
Company Name: CYBIN INC.
Stock Symbol: CYBN:CC
Market: AQNC
Menu
CYBN:CC CYBN:CC Quote CYBN:CC Short CYBN:CC News CYBN:CC Articles CYBN:CC Message Board
Get CYBN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
CYBN:CC - Cybin Announces Closing of Overnight Marketed Public Offering of Units

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce tha...
CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Details About Public Offering, Begins Dosing in Final Phase 2 Trial Cohort

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting the price and size of the public offering it announced earlier this week. Accordin...

CYBN:CC - Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder

- To date, CYB003 has demonstrated a robust psychedelic response and a favorable safety and tolerability profile at doses of up to 12mg - - Phase 2 topline efficacy data expected in Q3/Q4 2023 - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the &...

CYBN:CC - Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today the pricin...
CYBN:CC - Cybin Announces Overnight Marketed Public Offering of Units

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce tha...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plans to Participate in Annual Canaccord Genuity Growth Conference

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be represented at the upcoming 43rd annual Canaccord Genuity Growth Conference. The c...

CYBN:CC - Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Do...
CYBN:CC - Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

2023-07-26 08:45:24 ET Palm Beach, FL – July 26, 2023 – FinancialNewsMedia.com News Commentary – Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise in the coming yea...

CYBN:CC - Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder

-Collaboration with Worldwide Clinical Trials provides Cybin with access to a contract research organization with substantial experience supporting multinational psychedelic clinical trials - - Cybin expects to report Phase 2 topline efficacy data for CYB003 in major depressive disorder i...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Significant Milestone in Advancing CYB003 Towards Pivotal Studies

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that its phase 2 trial evaluating CYB003, an investigational pro...
Previous 10 Next 10